Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

Detalles Bibliográficos
Autores principales: Lambertini, Matteo, Viglietti, Giulia, de Azambuja, Evandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890055/
https://www.ncbi.nlm.nih.gov/pubmed/29636992
http://dx.doi.org/10.1136/esmoopen-2018-000350
_version_ 1783312792329125888
author Lambertini, Matteo
Viglietti, Giulia
de Azambuja, Evandro
author_facet Lambertini, Matteo
Viglietti, Giulia
de Azambuja, Evandro
author_sort Lambertini, Matteo
collection PubMed
description
format Online
Article
Text
id pubmed-5890055
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58900552018-04-10 Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? Lambertini, Matteo Viglietti, Giulia de Azambuja, Evandro ESMO Open Editorial BMJ Publishing Group 2018-03-29 /pmc/articles/PMC5890055/ /pubmed/29636992 http://dx.doi.org/10.1136/esmoopen-2018-000350 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Editorial
Lambertini, Matteo
Viglietti, Giulia
de Azambuja, Evandro
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
title Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
title_full Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
title_fullStr Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
title_full_unstemmed Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
title_short Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
title_sort controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890055/
https://www.ncbi.nlm.nih.gov/pubmed/29636992
http://dx.doi.org/10.1136/esmoopen-2018-000350
work_keys_str_mv AT lambertinimatteo controversiesinoncologywhichadjuvantendocrinetherapyistobegiventopremenopausalpatientswithhormonereceptorpositivebreastcancer
AT vigliettigiulia controversiesinoncologywhichadjuvantendocrinetherapyistobegiventopremenopausalpatientswithhormonereceptorpositivebreastcancer
AT deazambujaevandro controversiesinoncologywhichadjuvantendocrinetherapyistobegiventopremenopausalpatientswithhormonereceptorpositivebreastcancer

Ejemplares similares